DOI QR코드

DOI QR Code

Comparison of the Mortality and In-Hospital Outcomes of Preterm Infants Treated with Ibuprofen for Patent Ductus Arteriosus with or without Clinical Symptoms Attributable to the Patent Ductus Arteriosus at the Time of Ibuprofen Treatment

  • Yoo, Hani (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Lee, Jin A (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Oh, Sohee (Department of Biostatistics, Seoul National University Boramae Medical Center) ;
  • Jung, oung Hwa (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Sohn, Jin A (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Shin, Seung Han (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Choi, Chang Won (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kim, Ee-Kyung (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kim, Han-Suk (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kim, Beyong Il (Department of Pediatrics, Seoul National University College of Medicine)
  • Received : 2016.06.07
  • Accepted : 2016.09.09
  • Published : 2017.01.10

Abstract

The aim of this study was to assess the differences in the mortality and in-hospital outcomes of preterm infants with < 28 weeks of gestation who received ibuprofen treatment according to the presence of clinical symptoms (any of oliguria, hypotension, or moderate to severe respiratory difficulty) attributable to hemodynamically-significant patent ductus arteriosus (hsPDA) at the time of first ibuprofen treatment. In total, 91 infants born from April 2010 to March 2015 were included. Fourteen infants (15.4%) received ibuprofen treatment when there were clinical symptoms due to hsPDA (clinical symptoms group). In clinical symptoms group, infants were younger (25 [23-27] vs. 26 [23-27] weeks; P = 0.012) and lighter (655 [500-930] vs. 880 [370-1,780] grams; P < 0.001). Also, the clinical risk index for babies (CRIB)-II scores were higher and more infants received invasive ventilator care ${\leq}2$ postnatal days. More infants received multiple courses of ibuprofen in clinical symptoms group. Although the frequency of secondary patent ductus arteriosus (PDA) ligation and the incidence of bronchopulmonary dysplasia (BPD) was higher in the clinical symptoms group in the univariate analysis, after multivariate logistic regression analysis adjusting for the CRIB-II score, birthweight, birth year, and the invasive ventilator care ${\leq}2$ postnatal days, there were no significant differences in mortality, frequency of secondary ligation and in-hospital outcomes including necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), BPD or death. Our data suggest that we can hold off on PDA treatment until the clinical symptoms become prominent.

References

  1. Nemerofsky SL, Parravicini E, Bateman D, Kleinman C, Polin RA, Lorenz JM. The ductus arteriosus rarely requires treatment in infants > 1000 grams. Am J Perinatol 2008; 25: 661-6. https://doi.org/10.1055/s-0028-1090594
  2. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol 2012; 36: 123-9. https://doi.org/10.1053/j.semperi.2011.09.022
  3. Heuchan AM, Clyman RI. Managing the patent ductus arteriosus: current treatment options. Arch Dis Child Fetal Neonatal Ed 2014; 99: F431-6. https://doi.org/10.1136/archdischild-2014-306176
  4. Evans N. Preterm patent ductus arteriosus: a continuing conundrum for the neonatologist? Semin Fetal Neonatal Med 2015; 20: 272-7. https://doi.org/10.1016/j.siny.2015.03.004
  5. Clyman RI. The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia. Semin Perinatol 2013; 37: 102-7. https://doi.org/10.1053/j.semperi.2013.01.006
  6. Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol 2010; 30: 241-52. https://doi.org/10.1038/jp.2010.3
  7. Lee JA, Kim MJ, Oh S, Choi BM. Current status of therapeutic strategies for patent ductus arteriosus in very-low-birth-weight infants in Korea. J Korean Med Sci 2015; 30 Suppl 1: S59-66. https://doi.org/10.3346/jkms.2015.30.S1.S59
  8. Benitz WE; Committee on Fetus and Newborn, American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. Pediatrics 2016; 137: 1-6. https://doi.org/10.1542/peds.2015-4450
  9. Zonnenberg I, de Waal K. The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review. Acta Paediatr 2012; 101: 247 -51. https://doi.org/10.1111/j.1651-2227.2011.02468.x
  10. Flynn PA, da Graca RL, Auld PA, Nesin M, Kleinman CS. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005; 147: 38-42. https://doi.org/10.1016/j.jpeds.2005.03.040
  11. Kluckow M, Evans N. Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. J Pediatr 1995; 127: 774-9. https://doi.org/10.1016/S0022-3476(95)70172-9
  12. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007; 92: F424-7. https://doi.org/10.1136/adc.2007.118117
  13. Schena F, Francescato G, Cappelleri A, Picciolli I, Mayer A, Mosca F, Fumagalli M. Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia. J Pediatr 2015; 166: 1488-92. https://doi.org/10.1016/j.jpeds.2015.03.012
  14. Parry G, Tucker J, Tarnow-Mordi W; UK Neonatal Staffing Study Collaborative Group. CRIB II: an update of the clinical risk index for babies score. Lancet 2003; 361: 1789-91. https://doi.org/10.1016/S0140-6736(03)13397-1
  15. Sosenko IR, Fajardo MF, Claure N, Bancalari E. Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. J Pediatr 2012; 160: 929-935.e1. https://doi.org/10.1016/j.jpeds.2011.12.031
  16. Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. Pediatrics 2010; 125: e214-24. https://doi.org/10.1542/peds.2009-0913
  17. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, Brotherton T. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978; 187: 1-7. https://doi.org/10.1097/00000658-197801000-00001
  18. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723-9. https://doi.org/10.1164/ajrccm.163.7.2011060
  19. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92: 529-34. https://doi.org/10.1016/S0022-3476(78)80282-0
  20. Bose CL, Laughon MM. Patent ductus arteriosus: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed 2007; 92: F498-502. https://doi.org/10.1136/adc.2005.092734
  21. Sallmon H, Koehne P, Hansmann G. Recent advances in the treatment of preterm newborn infants with patent ductus arteriosus. Clin Perinatol 2016; 43: 113-29. https://doi.org/10.1016/j.clp.2015.11.008
  22. Sehgal A, McNamara PJ. Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus? Eur J Pediatr 2009; 168: 907-14. https://doi.org/10.1007/s00431-009-0983-3
  23. Jeong HA, Shin J, Kim E, Lee EH, Choi BM, Son CS, Lee JW. Correlation of B-type natriuretic peptide levels and echocardiographic parameters in preterm infants with patent ductus arteriosus. Korean J Pediatr 2016; 59: 183-9. https://doi.org/10.3345/kjp.2016.59.4.183
  24. Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, Lee JW. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005; 115: e255-61. https://doi.org/10.1542/peds.2004-1837
  25. Lee JH, Shin JH, Park KH, Rhie YJ, Park MS, Choi BM. Can early B-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants? Neonatology 2013; 103: 118-22. https://doi.org/10.1159/000343034
  26. Kim JS, Shim EJ. B-type natriuretic Peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants. Korean Circ J 2012; 42: 192-6. https://doi.org/10.4070/kcj.2012.42.3.192
  27. Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health 1994; 30: 406-11. https://doi.org/10.1111/j.1440-1754.1994.tb00689.x
  28. Jain A, Shah PS. Diagnosis, evaluation, and management of patent ductus arteriosus in preterm neonates. JAMA Pediatr 2015; 169: 863-72. https://doi.org/10.1001/jamapediatrics.2015.0987
  29. Nagasawa H, Terazawa D, Kohno Y, Yamamoto Y, Kondo M, Sugawara M, Koyama T, Miura R. Novel treatment criteria for persistent ductus arteriosus in neonates. Pediatr Neonatol 2014; 55: 250-5. https://doi.org/10.1016/j.pedneo.2013.10.009
  30. El Hajjar M, Vaksmann G, Rakza T, Kongolo G, Storme L. Severity of the ductal shunt: a comparison of different markers. Arch Dis Child Fetal Neonatal Ed 2005; 90: F419-22. https://doi.org/10.1136/adc.2003.027698
  31. Vanhaesebrouck S, Zonnenberg I, Vandervoort P, Bruneel E, Van Hoestenberghe MR, Theyskens C. Conservative treatment for patent ductus arteriosus in the preterm. Arch Dis Child Fetal Neonatal Ed 2007; 92: F244-7. https://doi.org/10.1136/adc.2006.104596
  32. Mirea L, Sankaran K, Seshia M, Ohlsson A, Allen AC, Aziz K, Lee SK, Shah PS; Canadian Neonatal Network. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. J Pediatr 2012; 161: 689-694.e1. https://doi.org/10.1016/j.jpeds.2012.05.007
  33. Sung SI, Choi SY, Park JH, Lee MS, Yoo HS, Ahn SY, Chang YS, Park WS. The timing of surgical ligation for patent ductus arteriosus is associated with neonatal morbidity in extremely preterm infants born at 23-25 weeks of gestation. J Korean Med Sci 2014; 29: 581-6. https://doi.org/10.3346/jkms.2014.29.4.581
  34. Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A; Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. J Pediatr 2007; 150: 229-34, 234.e1. https://doi.org/10.1016/j.jpeds.2006.11.039
  35. Lemmers PM, Benders MJ, D'Ascenzo R, Zethof J, Alderliesten T, Kersbergen KJ, Isgum I, de Vries LS, Groenendaal F, van Bel F. Patent ductus arteriosus and brain volume. Pediatrics 2016; 137: e20153090. https://doi.org/10.1542/peds.2015-3090
  36. Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2010: CD000174.
  37. Yeo MS, Choi K, Lee HJ, Park HK, Kim CR, Seol IJ. Effect of prophylactic ibuprofen in preterm infants less than 1,250 g in birth weight. J Korean Soc Neonatol 2011; 18: 234-9. https://doi.org/10.5385/jksn.2011.18.2.234
  38. Van Overmeire B, Van de Broek H, Van Laer P, Weyler J, Vanhaesebrouck P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001; 138: 205-11. https://doi.org/10.1067/mpd.2001.110528
  39. Candel-Pau J, Linde Sillo A, Castillo Salinas F, Coma Redon E, Ferrer Menduina Q, Albert DC. Early versus conventional treatment for patent ductus arteriosus in preterm infants. Am J Perinatol 2013; 30: 289-95.